trans-4-(4-(Cyclopropylmethyl)piperazin-1-yl)cyclohexan-1-amine hydrochloride(1:x)

Catalog No. :
ACTDXR057
CAS No. :
876371-19-6
Molecular Formula :
C14H28ClN3
Molecular Weight :
273.85

IUPAC Name:(1r,4r)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexan-1-amine hydrochloride

trans-4-(4-(Cyclopropylmethyl)piperazin-1-yl)cyclohexan-1-amine hydrochloride(1:x) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$458.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametrans-4-(4-(Cyclopropylmethyl)piperazin-1-yl)cyclohexan-1-amine hydrochloride(1:x)
IUPAC Name(1r,4r)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexan-1-amine hydrochloride
MDL No.MFCD16038984
Molecular FormulaC14H28ClN3
Molecular Weight273.85
SMILESCl.N[C@H]1CC[C@H](N2CCN(CC3CC3)CC2)CC1
InChI KeyMYCKNUSAHWIELF-SKKCDYJJSA-N
SynonymCyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, (Hydrochloride) , trans-;Trans-4-[4-(cyclopropylMethyl)-1-piperazinyl]-cyclohexanaMine hydrochloride (1:);trans-4-[4-(CyclopropylMethyl)-1-piperazinyl]-cyclohexanaMine hydrochloride (1:X)
CAS No.876371-19-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACTDXR057 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTDXR057 route product structure diagram
    ACTDXR057876371-19-6 In Stock
Inquiry

2. ACTDXR057 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTDXR057 route product structure diagram
    ACTDXR057876371-19-6 In Stock
Inquiry

Comments (0)